SRPT : Analysis & Opinions

  1. Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst ...

    December 18, 2014
    Pfizer (PFE) has moved its experimental Duchenne muscular dystrophy treatment into a phase II study.
  2. A Look Back At The Year In Biotech

    December 28, 2012
    Biotech stocks have been major outpeformers in 2012.
  3. Alexion Pharmaceuticals and More Big Movers in Healthcare on ...

    December 7, 2012
    So far today, the Nasdaq is down 0.7%, the S&P 500 is unchanged and the Dow is trading up 0.3%. The healthcare sector ...
Trading Center